An Open-label, Non-randomised Dose Escalation Study of KRN951 Administered Orally to Patients With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 16 Jun 2017
At a glance
- Drugs Tivozanib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Kyowa Hakko Kirin
- 03 Jan 2017 Status changed from active, no longer recruiting to completed.
- 13 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 07 Sep 2009 New trial record